— Know what they know.
Not Investment Advice

VNRX

VolitionRx Limited
1W: +1.6% 1M: -20.6% 3M: -24.2% YTD: -29.3% 1Y: -65.1% 3Y: -88.6% 5Y: -94.4%
$0.19
+0.00 (+0.89%)
 
AMEX · Healthcare · Medical - Diagnostics & Research · $19.2M · Alpha Radar Sell · Power 39
Smart Money Score
No convergence signal
Key Statistics
Market Cap$19.2M
52W Range0.17-0.94
Volume9,789,772
Avg Volume8,428,569
Beta1.36
Dividend
Analyst Ratings
5 Buy 2 Hold 0 Sell
Consensus Buy
Company Info
CEOCameron Reynolds
Employees85
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date2012-03-02
13215 Bee Cave Parkway
Henderson, TX 78738
US
646 650 1351
About VolitionRx Limited

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.

Recent Insider Trades

NameTypeSharesPriceDate
Forterre Gael F-InKind 5,251 $0.19 2026-03-17
Rootsaert Rodney Ger F-InKind 3,948 $0.19 2026-03-17
Micallef Jacob Vince F-InKind 5,310 $0.19 2026-03-17
Plummer Nicholas F-InKind 7,003 $0.19 2026-03-17
Rootsaert Rodney Ger F-InKind 3,321 $0.21 2026-03-01

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms